Royal FrieslandCampina has patented a method for producing hypoallergenic infant nutritional compositions based on cow’s milk protein. The process involves enzymatic treatment, clearing of allergenic components, and formulation for infants at risk of cow’s milk allergy. The method aims to provide a safe and nutritious alternative for infants with potential allergies. GlobalData’s report on Royal FrieslandCampina gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Royal FrieslandCampina, was a key innovation area identified from patents. Royal FrieslandCampina's grant share as of February 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Hypoallergenic infant nutritional composition manufacturing method
A recently granted patent (Publication Number: US11903392B2) outlines a method for manufacturing a hypoallergenic nutritional composition suitable for infants. The method involves providing a partial hydrolysate of milk protein(s) through enzymatic treatment, clearing out specific aggregates from the partial hydrolysate that can trigger allergic reactions, and formulating the cleared partial hydrolysate into a hypoallergenic nutritional composition. The clearing process includes filtering the partial hydrolysate using a membrane or subjecting it to size exclusion chromatography to remove problematic aggregates.
The patent further details the selection of bovine milk proteins, concentrating the cleared partial hydrolysate through methods like spray-drying, and the specific size distribution of peptides in the partial hydrolysate. Additionally, the method includes formulating the hypoallergenic nutritional composition by adding essential nutrients like carbohydrates, lipids, vitamins, and minerals, along with specific ingredients like galacto oligosaccharides (GOS), human milk oligosaccharides (HMOs), and TGFß. The resulting hypoallergenic nutritional composition can be used to prevent or delay sensitization in infants at risk of developing cow's milk allergy (CMA), particularly those with a genetic predisposition or family history of CMA.
To know more about GlobalData’s detailed insights on Royal FrieslandCampina, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
